Key Highlights
- A randomized, 30-patient IRB study found NEXGEL's hydrogel patch reduced laser plume concentration by 95.6% (p = 0.0001) versus a control, with results published in Lasers in Surgery and Medicine.
- NEXGEL reported Q1 2026 revenue of $2.65 million, a net loss of $927 thousand attributable to stockholders, and an unrestricted cash balance of just $208 thousand as of March 31, 2026, prompting explicit going-concern language in its 10-Q.
- The April 17, 2026 closing of a license and asset deal with Celularity Inc. formed BIONX Surgical, a regenerative-biomaterials division management says could roughly triple pro-forma annual revenue to about $35 million, financed through more than $8.5 million of new convertible notes.
- The headline data come from a randomized, single-center IRB study of 30 patients, conducted at the Florida Clinical Research Center by plastic surgeons Dr.
NEXGEL, Inc. (NASDAQ:NXGL), a Pennsylvania hydrogel maker, published clinical data on May 19, 2026 showing its laser-treatment patch cut plume concentration by 95.6% during laser hair removal. The finding lands weeks after the company closed a transformative acquisition that formed BIONX Surgical, even as its first-quarter 10-Q flags a going-concern warning tied to a $0.2 million cash position.
Why NEXGEL Is Suddenly on Investors' Radar
NEXGEL, Inc. (NXGL) has spent two decades as a low-profile contract manufacturer of electron-beam cross-linked hydrogels. That changed twice in rapid succession this year. On April 17, 2026, the Langhorne, Pennsylvania-based company closed a license and asset-purchase deal with Celularity Inc. (NASDAQ: CELU), forming a new division, BIONX Surgical, focused on regenerative biomaterials for tendon repair, soft-tissue reconstruction and bone regeneration. Then, on May 19, 2026, NEXGEL disclosed results from an independent, randomized clinical study showing its hydrogel laser-treatment patch reduced airborne "plume" (carcinogenic particulate released when lasers vaporize hair) by 95.6% versus control (p = 0.0001).
Together, the developments reposition a micro-cap consumer and contract-manufacturing name as a company chasing a foothold in surgical biomaterials and medical-device safety. The catalyst is real and independently published; investors must also weigh a balance sheet that carried only $208,000 of unrestricted cash and an explicit going-concern disclosure as of the most recent quarter.
Inside NEXGEL's (NXGL) Business Model
NEXGEL manufactures ultra-gentle, high-water-content hydrogels used in wound care, medical diagnostics, transdermal drug delivery and cosmetics. Its 10-Q for the quarter ended March 31, 2026 describes four lines of business: contract manufacturing, custom and white-label finished goods, consumer branded products (MedaGel, Kenkoderm and Silly George), and a nascent medical devices/other category including the plume-reduction patch. The company also consolidates a 50%-owned Texas converting and packaging joint venture, CGN JV. With Celularity, NEXGEL layered on BIONX Surgical, built around six licensed regenerative biomaterials products with existing reimbursement, plus three more 510(k) filings planned for 2026-2028.
The Plume-Reduction Catalyst, Verified
The headline data come from a randomized, single-center IRB study of 30 patients, conducted at the Florida Clinical Research Center by plastic surgeons Dr. Barry DiBernardo and Dr. Jason Pozner and funded by Innovative Optics, a laser-safety-equipment supplier. Per NEXGEL's May 19, 2026 release, the hydrogel patch reduced plume concentration by 95.6% versus control (p = 0.0001). Secondary endpoints were mixed: at 90 days, the treated side showed a 37.2% mean hair-density reduction versus 26.7% on control, not statistically significant (p = 0.3607).
Pain scores were lower on the treated side (3.5 versus 5.1, p = 0.0033), with no adverse events reported. The study was published in Lasers in Surgery and Medicine on March 30, 2026. CEO Adam Levy called the data "a major milestone for NEXGEL's medical device portfolio." The significance lies less in near-term revenue (medical devices/other generated just $113,000 of $2.65 million in first-quarter revenue) and more in clinical credibility NEXGEL (NXGL) can now market to laser-hair-removal and dermatology practices.
Latest Financial and Operational Performance
For the quarter ended March 31, 2026, NEXGEL reported net revenue of $2.65 million, down from $2.81 million a year earlier. By segment, the core NexGel business generated $1.945 million and the CGN JV contributed $705,000. Gross margin narrowed to $1.061 million from $1.188 million as volumes softened. Operating expenses of $2.019 million pushed the operating loss to $958,000, versus $777,000 a year earlier. Net loss attributable to NexGel stockholders was $927,000, or $0.11 per share, compared with $712,000, or $0.09 per share, previously.
Revenue, Profitability, Cash, Debt and Funding
NEXGEL's balance sheet as of March 31, 2026 showed total assets of $11.6 million against total liabilities of $7.1 million, leaving stockholders' equity of $4.48 million. More pressing: unrestricted cash stood at just $208,000, down from $317,000 at year-end 2025, while restricted cash tied to the CGN partnership rose to $1.9 million. Net cash used in operations was $504,000, and the 10-Q states that "these conditions raise substantial doubt about the Company's ability to continue as a going concern." Financing has since accelerated: NEXGEL raised a $7,375,000 convertible note offering on April 17, 2026 and a further $1,210,000 tranche on May 11, 2026, both at 10% interest and an 18-month maturity, paired with warrants.
The Celularity deal required $13.3 million upfront ($8.3 million cash plus a $5 million convertible note) with up to $17.5 million more in contingent milestones. Management expects improved liquidity, but the 10-Q states further capital raises "may be necessary."
Growth Opportunities and Upcoming Milestones
NEXGEL's near-term growth case rests on integrating BIONX Surgical, whose licensed products management describes as carrying existing reimbursement pathways; the company projects the deal could roughly triple pro-forma annual revenue to about $35 million, though that figure is a forward-looking estimate, not a reported result. NEXGEL appointed Dave Hazard, a 13-year orthobiologics sales veteran of Arthrex and Nuo Therapeutics, as BIONX Surgical's Vice President of Sales on May 13, 2026. Sequence LifeScience, which led the $5.5 million financing tied to the Celularity closing, will also serve as contract manufacturer. On the legacy side, the plume data give NEXGEL a fresh selling point to safety-conscious dermatology customers.
Material Company-Specific Risks
The most immediate risk is liquidity: with $208,000 of unrestricted cash and a stated going-concern doubt, NEXGEL depends on continued capital-markets access, and further raises are likely dilutive: shares outstanding rose from roughly 8.48 million at quarter-end to about 9.13 million by May 13, 2026, before the April and May notes and warrants convert. BIONX Surgical adds integration risk, up to $17.5 million of contingent milestones, and convertible instruments that could dilute further. The plume study, though statistically robust on its primary endpoint, was a single-center, 30-patient trial funded by an industry partner, and its secondary hair-reduction benefit was not significant. NEXGEL also carries customer concentration risk.
Outlook
In an upside scenario, BIONX Surgical's reimbursement-backed portfolio scales as planned, the Celularity deal proves accretive as management projects, and plume-patch data translate into device sales that diversify revenue beyond consumer products. In a base case, NEXGEL manages liquidity through further financing while integration proceeds gradually, keeping losses in line with recent quarters. In a downside scenario, integration costs and continued losses strain the going-concern position further, forcing dilutive raises on unfavorable terms. None of these paths implies a specific share-price outcome; investors should weigh progress against disclosed funding constraints.
Conclusion
NEXGEL, Inc. (NXGL) enters the second half of 2026 with a verified clinical win (a 95.6% reduction in laser plume concentration) and a freshly formed surgical division in BIONX Surgical. Whether NEXGEL becomes a genuine surgical-safety breakout depends on execution and funding as much as science: the same 10-Q describing the Celularity opportunity discloses a going-concern warning built on a $208,000 cash balance. For NXGL shareholders, integration progress and cash-burn trends over coming quarters will determine which narrative dominates.
This article is for informational purposes only and does not constitute investment advice or a recommendation to buy, sell, or hold any security. Share prices can rise or fall, and past performance does not guarantee future results. Investors should conduct independent research and consult a licensed financial adviser before making investment decisions.
_11_16_2026_14_38_45_453029.jpg)





Please wait processing your request...